Navigation Links
Mount Sinai researchers discover novel mechanisms that might causally link type-2 diabetes to Alzheimer's disease
Date:4/10/2009

A recent study by Mount Sinai faculty suggests that a gene associated with onset of type-2 diabetes also decreases in Alzheimer's disease dementia cases. The research, led by Dr. Giulio Maria Pasinetti, MD, Ph.D., The Aidekman Family Professor in Neurology, and Professor of Psychiatry and Geriatrics and Adult Development at Mount Sinai School of Medicine, was published this week in the scientific journal, Archives of Neurology.

"This new evidence is of extreme interest," Dr. Pasinetti tells us, "especially because of the evidence that approximately 60% of Alzheimer's disease dementia cases have at least one serious medical condition primarily associated with type-2 diabetes, a chronic condition which includes high blood glucose content (hyperglycemia) and reduced sensitivity to insulin, among other conditions."

"The relationship between type-2 diabetes and Alzheimer's disease is elusive," says Dr. Pasinetti. Not all subjects with type-2 diabetes are affected by Alzheimer's disease, and similarly, not all Alzheimer's disease cases are diabetic. However, in the last few years, epidemiological evidence indicates that, relative to healthy elderly subjects, people of the same age affected by type-2 diabetes are twice as likely to develop Alzheimer's disease dementia. The reason is not known. The new study from Dr. Pasinetti, reported in this week's issue of Archives of Neurology, provides insight into a potential mechanism that might explain the relationship between type-2 diabetes and Alzheimer's disease onset and progression.

Dr. Pasinetti and colleagues found that a gene known as proliferator-activated receptor coactivator 1 - (PGC-1 ), a key regulator of glucose content currently investigated as a potential therapeutic target for type-2 diabetes, is also decreased in Alzheimer' disease dementia cases. Most importantly, Dr. Pasinetti reports that PGC-1 decreased in Alzheimer' disease dementia cases with progression of the clinical disease and positively correlates with brain accumulation of β-amyloid, an abnormal protein highly linked to Alzheimer' disease dementia and brain degeneration. This evidence is of high interest to the field and suggests, for the first time, a strong relationship between decreased content of a gene responsible for type-2 diabetes in Alzheimer's disease dementia cases, says Dr. Pasinetti.

"Of considerable interest," continues Dr. Pasinetti, "is the evidence found in further mechanistic studies in our laboratory, indicating that promoting PGC-1 content in brain cells, using a transgenic mouse model of Alzheimer's disease, attenuates hyperglycemic-mediated production of β-amyloid, highly linked to Alzheimer' disease dementia. These findings are very exciting, and for the first time tentatively link type-2 diabetic metabolic defects to increasing dementia mediated by β-amyloid production."

The discovery in Dr. Pasinetti's laboratory has staggering societal implications: there are currently more than 5 million Americans affected by Alzheimer's disease dementia, and the disease incidence is expected to skyrocket in the three decades as the population ages. The question now is how we can translate this evidence into the development of novel approaches for disease prevention and treatment.

Dr. Pasinetti and his colleagues are optimistic that if they find that PGC-1α can be manipulated pharmacologically, these studies will provide important insights to be used in the formulation of novel treatments and possible preventative strategies in Alzheimer's disease.


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Obama Notre Dame Abortion Tension Mounts: Good Friday Protests at White House, and in Dallas, Los Angeles, and Fort Wayne
2. According to Frost & Sullivan, Mounting Clinical Evidence Underlines Benefits of Bone Growth and Spinal Fusion Stimulators
3. Mount Sinai first in US to implant FDA-cleared ring for mitral valve repair
4. Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA
5. U.S. Preventive Medicine(R), The Mount Sinai Medical Center Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services
6. Local Infertility Specialist, Dr. Rachel Bennett, Westchester Reproductive Medicine, Opens New Office in Mount Kisco
7. Astronauts on International Space Station lose alarming amounts of hipbone strength
8. Peanut Butter Product Recalls Mount
9. Identity Theft on Agenda at Rocky Mountain Dental Conference
10. Grubb & Ellis Healthcare REIT Acquires Mountain Plains Portfolio in Texas
11. White Mountains Re Announces Management Changes -- Chokel to Retire and Remain Risk Advisor at WTM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... after receiving cognitive rehabilitation, according to a study released today at the 1st ... cognitive rehabilitation programs are proven to be effective in improving cognitive function in ...
(Date:2/25/2017)... (PRWEB) , ... February 25, 2017 , ... FCPX users ... Color tools from Pixel Film Studios. With ProSharpen Color users have total control over ... easily refine their color range. With color spectrum tools users can visually see the ...
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... options at his office, Antoine Dental Center. Currently, patients can get single dental ... may apply, but patients can learn more about these offers by contacting Antoine ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... business development, education, networking and recognition opportunities as well as advocacy for the ... in Holmdel, NJ on February 23. The Council's Innovation Forecast event highlights ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, 2017 /PRNewswire/ ... company focused on developing cerebral embolic protection devices ... of the FDA,s Circulatory System Devices Panel that ... the need for cerebral protection following transcatheter aortic ... shared by this FDA panel support the need ...
(Date:2/27/2017)... Feb. 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL ) today ... Raymond James and Associates, 38 th ... 2017 in Orlando, FL. Cowen ... ET on March 7, 2017 in Boston, MA. ... 16, 2017 in Miami, FL. ...
(Date:2/27/2017)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced ... President and Chief Executive Officer (CEO) and member of the ... Richard Love , interim President and CEO who will ... Craig has over 20 years of experience in hematology, oncology ... Europe . "On behalf of CTI BioPharma,s ...
Breaking Medicine Technology: